CHRONOLOGY: Drug company Biovail's legal woes

TORONTO (Reuters) - The U.S. Securities and Exchange Commission charged Biovail Corp (BVF.TO) (BVF.N), two current senior executives and founder and former Chief Executive Eugene Melnyk on Monday with engaging in a number of fraudulent accounting schemes.

Following is a list of key dates of the drug company's legal issues:

March 24, 2008 - SEC charges Biovail and senior executives with accounting fraud. Company agrees to pay $10 million penalty to settle the charges.

March 24, 2008 - Ontario Securities Commission sets April 22 hearing date for Biovail insiders.

February 1, 2008 - Biovail faces U.S. grand jury probe over marketing of Cardizem heart drug.

December 11, 2007 - Biovail settles U.S. shareholder lawsuit that stretched back more than four years.

September 11, 2007 - Biovail settles with Banc of America Securities analyst.

May 18, 2007 - Ontario Securities Commission approves deal that settles trading disclosure allegations against company founder Eugene Melnyk.

February 22, 2006 - Biovail files lawsuit alleging stock market manipulation scheme.

November 20, 2003 - Biovail confirms informal inquiry by SEC into accounting and financial reporting practices.

August 22, 2003 - Biovail initially receives administrative inquiry from U.S. Office of the Inspector General into marketing programs related to Cardizem.

($1=$1.02 Canadian)

(Reporting by Scott Anderson; editing by Rob Wilson)